PL3359528T3 - Agonisty ppar, związki, kompozycje farmaceutyczne i sposoby ich stosowania - Google Patents
Agonisty ppar, związki, kompozycje farmaceutyczne i sposoby ich stosowaniaInfo
- Publication number
- PL3359528T3 PL3359528T3 PL16785611T PL16785611T PL3359528T3 PL 3359528 T3 PL3359528 T3 PL 3359528T3 PL 16785611 T PL16785611 T PL 16785611T PL 16785611 T PL16785611 T PL 16785611T PL 3359528 T3 PL3359528 T3 PL 3359528T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- ppar agonists
- ppar
- Prior art date
Links
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| EP16785611.1A EP3359528B1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3359528T3 true PL3359528T3 (pl) | 2022-05-30 |
Family
ID=57200096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16785611T PL3359528T3 (pl) | 2015-10-07 | 2016-10-05 | Agonisty ppar, związki, kompozycje farmaceutyczne i sposoby ich stosowania |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (pl) |
| EP (3) | EP3770146B1 (pl) |
| JP (2) | JP6657413B2 (pl) |
| KR (2) | KR102667386B1 (pl) |
| CN (3) | CN113004205B (pl) |
| AU (3) | AU2016333963C1 (pl) |
| BR (1) | BR112018006866B1 (pl) |
| CA (1) | CA3000431A1 (pl) |
| CO (1) | CO2018004473A2 (pl) |
| DK (1) | DK3359528T3 (pl) |
| EA (1) | EA037371B1 (pl) |
| ES (3) | ES2906379T3 (pl) |
| HU (1) | HUE058154T2 (pl) |
| IL (3) | IL258225B (pl) |
| JO (3) | JO3738B1 (pl) |
| MA (2) | MA52648A (pl) |
| MX (3) | MX392524B (pl) |
| MY (1) | MY203081A (pl) |
| PH (1) | PH12018500762A1 (pl) |
| PL (1) | PL3359528T3 (pl) |
| PT (1) | PT3359528T (pl) |
| SG (1) | SG10201906400SA (pl) |
| TW (3) | TWI730408B (pl) |
| UA (1) | UA122237C2 (pl) |
| WO (1) | WO2017062468A1 (pl) |
| ZA (4) | ZA201802029B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52648A (fr) | 2015-10-07 | 2021-10-13 | Mitobridge Inc | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation |
| JP6925367B2 (ja) | 2016-04-13 | 2021-08-25 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
| WO2018067860A1 (en) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| DK3522880T3 (en) * | 2016-10-05 | 2021-01-18 | Mitokyne Inc | Methods of treating acute kidney injury |
| US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| US20240358681A1 (en) | 2021-06-02 | 2024-10-31 | Mitobridge, Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| ES2334101T3 (es) | 2000-08-17 | 2010-03-05 | Pfizer Limited | Imidazoles sustituidos como inhibidores de tafia. |
| ES2342596T3 (es) * | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
| EP1553075B1 (en) | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| MXPA06003357A (es) | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
| KR20070047338A (ko) | 2004-09-06 | 2007-05-04 | 에프. 호프만-라 로슈 아게 | 4-아미노메틸 벤즈아미딘 유도체 및 그의 ⅶａ 인자억제제로서의 용도 |
| BRPI0606997A2 (pt) | 2005-02-15 | 2009-07-28 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos |
| BRPI0615948A2 (pt) | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
| BRPI0707338A2 (pt) | 2006-01-30 | 2011-05-03 | Transtech Pharma Inc | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase |
| US20100261758A1 (en) | 2006-03-28 | 2010-10-14 | Novartis Ag | Heterocyclic amides for use as pharmaceuticals |
| KR101507173B1 (ko) | 2006-04-18 | 2015-03-30 | 닛뽕 케미파 가부시키가이샤 | 페록시좀 증식제 활성화 수용체 δ 의 활성화제 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
| AU2008221718A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| EP2234622A4 (en) | 2007-12-28 | 2011-03-09 | Salk Inst For Biological Studi | METHODS ENHANCING PERFORMANCE AND MUSCLE TONUS |
| JP5895104B2 (ja) | 2012-08-28 | 2016-03-30 | コチ・ウニヴェルシテシＫｏｃ Ｕｎｉｖｅｒｓｉｔｅｓｉ | 骨板 |
| CA2908695A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| MA52648A (fr) * | 2015-10-07 | 2021-10-13 | Mitobridge Inc | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation |
| JP6925367B2 (ja) | 2016-04-13 | 2021-08-25 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
| DK3522880T3 (en) | 2016-10-05 | 2021-01-18 | Mitokyne Inc | Methods of treating acute kidney injury |
| WO2018067860A1 (en) * | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| PL3562822T3 (pl) * | 2016-12-30 | 2021-09-13 | Mitobridge, Inc. | Inhibitory polimerazy poli(adp-rybozy) (parp) |
-
2016
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003662B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| IL254124A0 (en) | New 3-indole-transformed histories, medicinal preparations and methods of use | |
| EP3139920A4 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
| IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
| EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| EP3285758A4 (en) | Co-crystal composition and its pharmaceutical use | |
| EP3151826A4 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| IL248578A0 (en) | Quinzoline derivatives, pharmaceutical compounds containing them and their uses | |
| PL3302483T3 (pl) | Kompozycje farmaceutyczne i ich zastosowanie | |
| RO130539B8 (ro) | Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia | |
| ZA201801649B (en) | Composition for minimum quantity lubrication, and use of same | |
| EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| GB201408233D0 (en) | Use of polyanionic composition | |
| GB201720445D0 (en) | Use of TRPV1 agonists | |
| GB201620933D0 (en) | Use of TRPV1 agonists | |
| PL3061765T3 (pl) | Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek | |
| GB201415969D0 (en) | Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof | |
| TH149389B (th) | องค์ประกอบสารเคลือบใส กระบวนการสำหรับการเตรียมและการใช้ | |
| HK1234671A1 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| HK1233497A1 (en) | Compositions of selenoorganic compounds and methods of use thereof |